Advertisements



Alnylam"s LDL-Lowering Drug Positive in Phase II Study

Alnylam Pharmaceuticals, Inc. (ALNY) and its partner T.....»»

Category: topSource: zacksMar 20th, 2017

Alnylam"s LDL-Lowering Drug Positive in Phase II Study

Alnylam Pharmaceuticals, Inc. (ALNY) and its partner T.....»»

Category: topSource: zacksMar 20th, 2017

The Medicines Co LDL-Lowering Drug Positive in Phase II

The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for .....»»

Category: topSource: zacksJan 9th, 2017

Zogenix (ZGNX) Stock Skyrocketed Over 170% Today: Here"s Why

On Friday, shares of pharmaceutical company Zogenix Inc. (ZGNX) are skyrocketing after it announced positive results from its first Phase 3 study of ZX008, a drug used to treat the rare epilepsy form Dravet Syndrome. On Friday, sha.....»»

Category: worldSource: nytSep 29th, 2017

Roche (RHHBY) Announces Positive Data on Leukemia Drug

Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta. Roche Holdings AG RHHBY announced positive results from the phase III study, MURANO.The study evaluated Vencle.....»»

Category: personnelSource: nytSep 19th, 2017

Novartis Announces Positive Data on Urticaria Drug Xolair

Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA. .....»»

Category: smallbizSource: nytSep 18th, 2017

Alnylam Pharmaceuticals (ALNY) & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study - Presentation

Alnylam Pharmaceuticals (ALNY) & Sanofi Genzyme Report Positive Results from Ongoing Phase 2 Open-Label Extension Study - Presentation.....»»

Category: topSource: seekingalphaJul 11th, 2017

Arena Pharmaceuticals stock skyrockets on positive hypertension-drug study

Arena Pharmaceuticals Inc. shares jumped 35% in late trading Monday after the company announced positive results from a drug study. The San Diego company said that a phase 2 study of a drug targeted at pulmonary arterial hyperte.....»»

Category: topSource: marketwatchJul 10th, 2017

Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug. Shares of Novartis AG NVS .....»»

Category: topSource: zacksJun 26th, 2017

Novartis Announces Positive Results for Cardiovascular Drug

Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascu.....»»

Category: topSource: zacksJun 22nd, 2017

Novartis Presents Positive Data on CAR-T Cell Therapy Drug

Novartis AG (NVS) announced data from an interim analysis from a phase II study on lymphoma candidate. Novartis AG NVS announced data from an interim analysis from its multi-center global phase II study, JULTIET (NCT02445248). The study e.....»»

Category: topSource: zacksJun 12th, 2017

Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs

Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosuma.....»»

Category: topSource: zacksJun 5th, 2017

Eli Lilly"s (LLY) Cancer Drug Cyramza Positive in Phase III

Eli Lilly and Company (LLY) announced positive results from a phase III study evaluating Cyramza for expanded use in combinatio.....»»

Category: topSource: zacksJun 1st, 2017

Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study

Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy. .....»»

Category: smallbizSource: nytMay 23rd, 2017

Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

Zacks.....»»

Category: topSource: redinewsMay 20th, 2017

Shire (SHPG) Up on Positive Phase III Study Data on HAE Drug

Shire plc (SHPG) announced positive top-line results from the phase III study, HELP, on HAE candidate, lanadelumab. Shire plc SHPG announced positive top-line results from the phase III study, HEL.....»»

Category: topSource: zacksMay 19th, 2017

Ultragenyx"s Hypophosphatemia Drug Succeeds in Phase III

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Hakko Kirin Co., Ltd announced positive data from a phase III study evaluating its pipeline candidate burosumab (KRN23) in adults with X-linked.....»»

Category: topSource: zacksApr 19th, 2017

Roche"s Hemophilia A Drug Positive in Second Phase III Study

Zacks.....»»

Category: topSource: redinewsApr 18th, 2017

Roche"s Hemophilia A Drug Positive in Second Phase III Study

Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis. Roche H.....»»

Category: topSource: zacksApr 17th, 2017

Ultragenyx"s (RARE) XLH Drug Positive in Phase II Study

Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese .....»»

Category: topSource: zacksApr 10th, 2017

Roche Announces Positive Data on Lung Cancer Drug Alecensa

Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa. Roche Holdings AG RHHBY recently announced encouraging results from the phase III study, ALUR on l.....»»

Category: topSource: zacksApr 5th, 2017